Floatz logo

TIL

Hepatic Carcinoma

CAR-T (Shanghai) Cell Biotechnology Co., Ltd.Cell therapyPhase 1/2Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
95/ 100

Competitive context

521 Active assets in the Hepatic Carcinoma cohort.

Asset / SponsorPhaseRating
Adefovir
Bukwang Pharmaceutical
Phase 4BBB
Huaier Granule
Tongji Hospital
Phase 4BBB
Sorafenib
Bayer
Phase 4BBB
Carboplatin
AstraZeneca
Phase 4BB
Theprubicin
RWTH Aachen University
Phase 4BB

View all 50 →

Same molecule, other indications

TIL is also rated in:

cutaneous melanomaDormant
BBB
Indicative ·
72 / 100
View asset →
ovarian cancerDormant
BB
Indicative ·
70 / 100
View asset →
metastatic melanomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →